Combination chemotherapy of advanced colorectal cancer with triazinate and ICRF-159 after failure of 5-Fluorouracil.
13 patients with advanced measurable colorectal cancer, having failed chemotherapy including fluorouracil, were treated on a weekly schedule with ICRF-159, 1.0 g/m2, and triazinate, 250 mg/m2. Only 1 patient had an objective partial remission, lasting 6 months. Toxicity was moderate, but acceptable. Since each of these drugs had been reported to have a 14-17% response rate in similar patient populations, the combination in the present schedule would appear to offer no benefit compared to the single agents, and cannot be recommended for further use in failure of 5-Fluorouracil therapy.
D002986:Clinical Trials as Topic; D003110:Colonic Neoplasms / Q000188:drug therapy*; D003967:Diarrhea / Q000139:chemically induced; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005472:Fluorouracil / Q000627:therapeutic use; D005493:Folic Acid Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D009325:Nausea / Q000139:chemically induced; D010879:Piperazines / Q000627:therapeutic use*; D011929:Razoxane / Q000009:adverse effects / Q000627:therapeutic use*; D012004:Rectal Neoplasms / Q000188:drug therapy*; D013921:Thrombocytopenia / Q000139:chemically induced; D014227:Triazines / Q000009:adverse effects / Q000627:therapeutic use*
D005493:Folic Acid Antagonists; D010879:Piperazines; D014227:Triazines; D011929:Razoxane; C012071:triazinate; D005472:Fluorouracil